GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing to raise ?2.9 million

26 Feb 2010 07:00

RNS Number : 7099H
ViaLogy PLC
26 February 2010
 



ViaLogy PLC ("ViaLogy")

Placing to raise £2.9 million 

 

London, February 25, 2010. ViaLogy (LSE:VIY) is pleased to announce that it has today raised approximately £2.88 million (gross) through the placing of 59,118,858 new ordinary shares of 1p each ("Placing Shares") at a price of 4.875p per share with certain existing shareholders ("the Placing").

The net proceeds of the Placing will be used in the further expansion of ViaLogy's Energy business which uses its proprietary QuantumRD™ technology to interpret seismic data for the location and analysis of oil well sites, as well as for general working capital purposes. 

Application has been made for the 59,118,858 Placing Shares to be admitted to trading on AIM and dealings are expected to commence on March 2, 2010. Following the Placing, the total number of ordinary shares in issue and therefore the total number of voting rights is 690,475,334

Terry Bond, chairman of ViaLogy commented: "The continuing success of ViaLogy's QuantumRD technology, and its ability to accurately predict the correct locations for well drillings in order to maximise the commercial potential of oil and gas deposits, is causing considerable interest in the O&G industry globally.

"To date we have concentrated our activities in Texas, where there are significant oil deposits in a wide variety of formations and at varying depths. In a state where the strike rate averages around 40% our first five analyses have all been successful. Our achievement is being recognised by exploration companies around the world and the additional funding will be used in part to expand ViaLogy's ability to handle the increased demand for its services."

The Company is recruiting additional geophysicists and mathematicians and acquiring additional sophisticated computer equipment. 

 

For further information please contact:

ViaLogy PLC 

 

 

 

 

 

Robert W Dean, President & CEO

 

US +1 626 296 6337

 

 

(mobile: +1 703 589 3807)

 

 

 

Terry Bond, Chairman - UK & Europe

 

+44 (0) 1235 834734

 

 

(mobile: 07860 842 756) 

 

 

 

Seymour Pierce Limited

Nominated Advisor and Broker to ViaLogy

 

 

 

 

 

Mark Percy / Catherine Leftley

 

+44 (0) 207 107 8000

 

 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOETAMFTMBITBRM
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.